GLAXOSMITHKLINE (GSK) has announced that the Therapeutic Goods Association (TGA) has approved Shingrix, a non-live, recombinant subunit vaccine for the prevention of shingles (herpes zoster) and post-herpetic neuralgia in adults aged 50 years or older.
At this stage, however, only Seqirus' live attenuated varicella zoster vaccine Zostavax is funded on the National Immunisation Program (NIP) for shingles for eligible 70-79 year-olds.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Jul 18